Immunocore Holdings plc Research And Development Expense
Immunocore Holdings plc (IMCR) reported Research And Development Expense of GBP 28.77 million for the 3-month period ending 2023-06-30, per its 6-K filed 2023-08-10.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2023-08-10
- Immunocore Holdings plc research and development expense for the quarter ending 2023-06-30 was 28.77M GBP, a 42.76% increase year-over-year.
- Immunocore Holdings plc research and development expense for the quarter ending 2022-12-31 was 27.14M GBP, a 35.20% increase year-over-year.
- Immunocore Holdings plc research and development expense for the quarter ending 2022-09-30 was 23.30M GBP, a 38.71% increase year-over-year.
- Immunocore Holdings plc research and development expense for the quarter ending 2022-06-30 was 20.15M GBP.
| Period end | Research And Development Expense 3 month | Research And Development Expense 6 month | Research And Development Expense 9 month | Research And Development Expense 12 month |
|---|---|---|---|---|
| 2023-06-30 | 28.77M GBP 6-K · filed 2023-08-10 | 57.22M GBP 6-K · filed 2023-08-10 | ||
| 2022-12-31 | 27.14M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | 50.44M GBP derived: sum of 2 quarters · filed 2023-03-01 | 70.59M GBP derived: sum of 3 quarters · filed 2023-08-10 | 89.17M GBP 20-F · filed 2023-03-01 |
| 2022-09-30 | 23.30M GBP 6-K/A · filed 2022-11-18 | 43.45M GBP derived: sum of 2 quarters · filed 2023-08-10 | 62.03M GBP 6-K/A · filed 2022-11-18 | |
| 2022-06-30 | 20.15M GBP 6-K · filed 2023-08-10 | 38.73M GBP 6-K · filed 2023-08-10 | ||
| 2021-12-31 | 20.07M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | 36.87M GBP derived: sum of 2 quarters · filed 2023-03-01 | 73.23M GBP 20-F · filed 2023-03-01 | |
| 2021-09-30 | 16.80M GBP 6-K/A · filed 2022-11-18 | 53.15M GBP 6-K/A · filed 2022-11-18 | ||
| 2020-12-31 | 74.81M GBP 20-F · filed 2023-03-01 | |||
| 2019-12-31 | 99.99M GBP 20-F · filed 2022-03-03 | |||
| 2018-12-31 | 83.58M GBP 20-F · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |